The Medical Letter on Drugs and Therapeutics
Aliskiren/Amlodipine (Tekamlo): Another Combination Tablet for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Tekamlo (Novartis), an oral fixed-dose combination of the direct renin inhibitor aliskiren (Tekturna) and the calcium channel blocker amlodipine (Norvasc, and others), for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and as initial therapy in those likely to need multiple drugs to control their blood pressure (BP). Both aliskiren and amlodipine are available in combinations with other antihypertensive agents.1

CLINICAL STUDIES — A large trial randomized 5549 patients with hypertension (diastolic BP 90-109 mm Hg) to various doses of aliskiren/amlodipine (150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg), aliskiren alone (150 or 300 mg) or amlodipine alone (5 or 10 mg), or to placebo; the combination lowered systolic BP by 14-17 mm Hg and diastolic by 9-11 mm Hg more than ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aliskiren Amlodipine (Tekamlo): Another Combination Tablet for Hypertension
Article code: 1352c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian